Skip to content
2000
Volume 7, Issue 2
  • ISSN: 1389-2037
  • E-ISSN: 1875-5550

Abstract

The application of recombinant immunotoxin and radioimmunoconjugate in Cancer therapy has revived the "magic bullet" concept predicted a century ago. Many of the recombinant antibodies have received FDA approval for various indication of cancer in recent years and numerous others are in clinical trials.

Loading

Article metrics loading...

/content/journals/cpps/10.2174/138920306776359768
2006-04-01
2025-09-08
Loading full text...

Full text loading...

/content/journals/cpps/10.2174/138920306776359768
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test